NCT02317770

Brief Summary

This study compares the effect of nebulized lidocaine and lidocaine spray in patients undergoing esophago-gastro-duodenoscopy. The investigators evaluate the success rate of the procedure between two methods.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Nov 2013

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

December 11, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 16, 2014

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2016

Completed
Last Updated

March 16, 2016

Status Verified

March 1, 2016

Enrollment Period

2.3 years

First QC Date

December 11, 2014

Last Update Submit

March 15, 2016

Conditions

Keywords

lidocaine, esophago-gastro-duodenoscopy

Outcome Measures

Primary Outcomes (1)

  • Comparison of Topical and Nebulized Anesthesia

    Both nurse anesthetist and endoscopist evaluate difficulty during the procedure and demand for additional sedative drugs using numeric scale

    90 min

Secondary Outcomes (2)

  • Patient Satisfaction

    90 min

  • Operator Satisfaction

    30 min

Study Arms (2)

Lidocaine Spray

ACTIVE COMPARATOR

20 puffs of 10% Lidocaine spray

Drug: Lidocaine Spray

Nebulized Lidocaine

ACTIVE COMPARATOR

2.5 mL of 10% Lidocaine

Drug: Nebulized Lidocaine

Interventions

5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.

Also known as: Xylocaine Spray
Lidocaine Spray

The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.

Also known as: Nebulized Xylocaine
Nebulized Lidocaine

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • elective case for esophago-gastro-duodenoscopy with ASA classification 1-2
  • Both genders
  • Age between 18-65 years

You may not qualify if:

  • History of smoking
  • Upper respiratory tract infection
  • Asthma
  • Heart disease
  • Allergy to local anesthetic drugs
  • Withdrawal or termination criteria
  • Patient refusal
  • Patient develops lidocaine allergy
  • Bronchospasm
  • Sign of Local Anesthetic Toxicity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine Siriraj Hospital

Bangkoknoi, Bangkok, 10700, Thailand

RECRUITING

Related Publications (2)

  • Korttila K, Tarkkanen J, Tarkkanen L. Comparison of laryngotracheal and ultrasonic nebulizer administration of lidocaine in local anaesthesia for bronchoscopy. Acta Anaesthesiol Scand. 1981 Apr;25(2):161-5. doi: 10.1111/j.1399-6576.1981.tb01628.x.

    PMID: 7324824BACKGROUND
  • Dhir V, Swaroop VS, Vazifdar KF, Wagle SD. Topical pharyngeal anesthesia without intravenous sedation during upper gastrointestinal endoscopy. Indian J Gastroenterol. 1997 Jan;16(1):10-1.

    PMID: 9167371BACKGROUND

Study Officials

  • Papiroon Noitasaeng, RN

    Department of Anesthesia, Faculty of Medicine Siriraj Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Papiroon Noitasaeng, RN

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 11, 2014

First Posted

December 16, 2014

Study Start

November 1, 2013

Primary Completion

March 1, 2016

Study Completion

April 1, 2016

Last Updated

March 16, 2016

Record last verified: 2016-03

Locations